 Akebia Therapeutics Inc NASDAQ: AKBA and Otsuka Holdings OTC: OTSKY separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to Akebia on May 12 that the partnership had been terminated. 